Patent Assignment
Reel/Frame 057111/0242
Security Interest
Recorded: 2021-08-06
Pages: 16
Assignee
ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
601 LEXINGTON AVENUE, 54TH FLOOR, C/O ORBIMED ADVISORS LLC, NEW YORK, NEW YORK, 10022
Covered Properties
(56)
Absorption Enhancers for Drug Administration
Application:
16/898,365 →
Publication:
US US20210121573A1
Compositions, Devices and Methods for the Treatment of Alcohol Use Disorder
Application:
16/311,944 →
Publication:
US US20190209464A1
Compositions, Devices, and Methods for the Treatment of Opioid-Receptor-Mediated Conditions
Application:
17/024,149 →
Publication:
US US20210077382A1
Compositions and Methods for the Treatment of Opioid Overdose
Formulations and Methods for the Prevention of Opioid Overdose
Application:
17/055,647 →
Publication:
US US20210220346A1
Compositions, Devices, and Methods for the Treatment of Overdose and Reward-Based Disorders
Application:
16/721,872 →
Publication:
US US20200390691A1
Peptide Compositions and Methods of Use
Application:
16/615,362 →
Publication:
US US20200197494A1
Compositions for Drug Administration
Intranasal Epinephrine Formulations and Methods for the Treatment of Disease
Compositions for Drug Administration
Intranasal Epinephrine Formulations and Methods for the Treatment of Disease
Oil-Soluble Drug Containing Compositions and Methods of Use Thereof
Application:
16/875,683 →
Publication:
US US20200360292A1
Methods and Compositions for Rapid Delivery of Anti-Seizure Therapeutics
Application:
63/135,291 →
Multimodal Particulate Formulations
Application:
16/594,897 →
Publication:
US US20200038320A1
Administration of Benzodiazepine Compositions
Administration of Benzodiazepine Compositions
Administration of Benzodiazepine Compositions
Methods and Compositions for Treating Seizure Disorders in Pediatric Patients
Application:
63/209,092 →
Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors
Rho Kinase Inhibitor Ba-1049 (R) and Active Metabolites Thereof
Absorption Enhancers for Intranasal Interferon Administration
Absorption Enhancers for Intranasal Administration
Pharmaceutical Composition Including Alkyl Glycoside and an Anti-Seizure Agent
Antibacterial Compositions for Drug Administration
Controlled Release Formulations
Controlled Release Formulations
Intranasal Administration of Active Agents to the Central Nervous System
Compositions for Drug Administration
Alkylglycoside Compositions for Drug Administration
Compositions for Drug Administration
Compositions for Drug Administration
Compositions for Oral Drug Administration
Stabilizing Alkylglycoside Compositions and Methods Thereof
Stabilizing Alkylglycoside Compositions and Methods Thereof
Stabilizing Alkylglycoside Compositions and Methods Thereof
Stabilizing Alkylglycoside Compositions and Methods Thereof
Stabilizing Alkylglycoside Compositions and Methods Thereof
Stabilizing Alkylglycoside Compositions and Methods Thereof
Stabilizing Alkylglycoside Compositions and Methods Thereof
Stabilizing Alkylglycoside Compositions and Methods Thereof
Stabilizing Alkylglycoside Compositions and Methods Thereof
Stabilizing Alkylglycoside Compositions and Methods Thereof
Compositions for Drug Administration
Absorption Enhancers for Drug Administration
Stabilizing Alkylglycoside Compositions and Methods Thereof
Multimodal Particulate Formulations
Administration of Benzodiazepine Compositions
Administration of Benzodiazepine Compositions
4-Substituted Piperidine Derivatives
Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors
Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors
Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors
Rho Kinase Inhibitor Ba-1049 (R) and Active Metabolites Thereof
Rho Kinase Inhibitor Ba-1049 (R) and Active Metabolites Thereof
Kinase Inhibitors for Treatment of Disease
Oil-Soluble Drug Containing Compositions and Methods of Use Thereof
PCT:
PCT/US2020/033201 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Feb 5, 2019
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 048239/0658 →
Assignment of Assignor's Interest
Oct 7, 2019
From: CRYSTAL, ROGER
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 050642/0976 →
Assignment of Assignor's Interest
Oct 7, 2019
From: CARTT, STEVE; MEDEIROS, DAVID
To: HALE BIOPHARMA VENTURES, LLC
Reel/Frame 050644/0198 →
Assignment of Assignor's Interest
Oct 7, 2019
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 050644/0136 →
Assignment of Assignor's Interest
Oct 7, 2019
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 050642/0358 →
Assignment of Assignor's Interest
Oct 7, 2019
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 050639/0392 →
Assignment of Assignor's Interest
Oct 7, 2019
From: CRYSTAL, ROGER
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 050639/0758 →
Assignment of Assignor's Interest
Oct 16, 2019
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 050740/0096 →
Assignment of Assignor's Interest
Oct 16, 2019
From: CRYSTAL, ROGER; AGRAWAL, ARVIND
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 050740/0107 →
Assignment of Assignor's Interest
Nov 11, 2019
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 050976/0039 →
Assignment of Assignor's Interest
May 1, 2020
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 052548/0236 →
Assignment of Assignor's Interest
May 1, 2020
From: LOWENTHAL, RICHARD; SHAH, PRATIK; BELL, ROBERT G.
To: ARS PHARMACEUTICALS INC.
Reel/Frame 052548/0187 →
Assignment of Assignor's Interest
May 1, 2020
From: ARS PHARMACEUTICALS INC.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 052548/0243 →
Assignment of Assignor's Interest
Jun 3, 2020
From: LOWENTHAL, RICHARD; SHAH, PRATIK; BELL, ROBERT G.
To: ARS PHARMACEUTICALS INC.
Reel/Frame 052818/0197 →
Assignment of Assignor's Interest
Jun 3, 2020
From: ARS PHARMACEUTICALS INC.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 052818/0211 →
Assignment of Assignor's Interest
Jun 3, 2020
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 052818/0213 →
Assignment of Assignor's Interest
Jul 24, 2020
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 053306/0366 →
Assignment of Assignor's Interest
Jul 24, 2020
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 053305/0980 →
Assignment of Assignor's Interest
Aug 6, 2020
From: CRYSTAL, ROGER; ELLISON, MARK; SKOLNICK, PHIL
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 053419/0829 →
Assignment of Assignor's Interest
Aug 6, 2020
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 053419/0262 →
Assignment of Assignor's Interest
Dec 3, 2020
From: CRYSTAL, ROGER
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 054526/0623 →
Assignment of Assignor's Interest
Dec 3, 2020
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 054526/0647 →
Security Interest
Dec 10, 2020
From: OPIANT PHARMACEUTICALS, INC.
To: PONTIFAX MEDISON FINANCE GP, L.P.
Reel/Frame 054602/0192 →
Assignment of Assignor's Interest
Jan 12, 2021
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 054884/0859 →
Assignment of Assignor's Interest
Jan 14, 2021
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS LLC
Reel/Frame 054915/0209 →